Today's Top Performers In Drugs

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 44 points (0.3%) at 15,464 as of Tuesday, Aug. 13, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,183 issues advancing vs. 1,800 declining with 78 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Osiris Therapeutics ( OSIR), up 112.4%, Novo Nordisk A/S ( NVO), up 0.7% and AstraZeneca ( AZN), up 0.6%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry higher today. As of noon trading, GlaxoSmithKline is up $0.54 (1.1%) to $51.84 on average volume. Thus far, 1.4 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $51.42-$51.94 after having opened the day at $51.64 as compared to the previous trading day's close of $51.30.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $126.4 billion and is part of the health care sector. Shares are up 18.5% year to date as of the close of trading on Monday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $1.05 (1.0%) to $103.00 on average volume. Thus far, 973,974 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $101.75-$103.45 after having opened the day at $102.43 as compared to the previous trading day's close of $101.95.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $33.9 billion and is part of the health care sector. Shares are up 70.6% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Eli Lilly and Company ( LLY) is up $2.11 (3.9%) to $55.67 on heavy volume. Thus far, 9.0 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $55.42-$56.50 after having opened the day at $56.00 as compared to the previous trading day's close of $53.56.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $61.0 billion and is part of the health care sector. Shares are up 9.9% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Eli Lilly and Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is up $3.74 (1.8%) to $210.63 on average volume. Thus far, 830,371 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $206.15-$210.92 after having opened the day at $206.88 as compared to the previous trading day's close of $206.89.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $50.5 billion and is part of the health care sector. Shares are up 45.1% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.54 (0.6%) to $92.54 on average volume. Thus far, 4.0 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.9 million shares. The stock has ranged in price between $91.76-$92.56 after having opened the day at $92.02 as compared to the previous trading day's close of $92.00.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $260.3 billion and is part of the health care sector. Shares are up 31.2% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade